Precision Botanical Drug Discovery Powered by the Synergistic Compatibility Framework (SCF)

At SCF BIOTECH Therapeutics, we transform traditional medicinal knowledge into next-generation pharmaceutical innovation. Our Maytenus krukovii Therapeutic Platform is a flagship program combining ethnobioprospecting, advanced molecular engineering, and AI-guided synergy design to develop targeted therapies for inflammatory, autoimmune, and oncology indications.

Platform Overview

The Maytenus krukovii platform leverages bioactive triterpenoids discovered in Amazonian ethnomedicine and re-engineers them into modern therapeutic agents.

Our Integrated Drug Development Strategy

Three complementary product modalities:

This integrated approach enables higher therapeutic potency, improved safety, and precision targeting of disease pathways.

Lead Drug Candidate

MK-PD2 – Targeted Prodrug Therapy

Our lead candidate, MK-PD2, is a protease-activated prodrug engineered from the Maytenus krukovii triterpenoid scaffold.

Key Innovation

MK-PD2 remains inactive until it reaches disease-associated protease environments such as:

• inflamed tissues
• tumor microenvironments
• fibrotic lesions

Once activated, MK-PD2 releases the active therapeutic compound directly at the disease site.

Advantages

• Targeted drug activation
• Reduced systemic toxicity
• Improved pharmacokinetics
• Higher therapeutic precision

Mechanism of Action

The Maytenus krukovii pharmacophore acts on critical inflammatory and disease signaling networks.

Primary Molecular Targets

This multi-pathway approach allows broad therapeutic impact while maintaining molecular precision.

Pipeline Candidates

Our platform currently includes multiple therapeutic candidates in development.

SCF Potency Optimization

All candidates are evaluated using the SCF Quantified Potency Score (QPS), an advanced scoring system integrating:

• molecular interaction density
• pharmacokinetic coherence
• multi-pathway synergy
• safety compatibility

Lead Candidate Performance

MK-PD2 QPS Score

635 / 1000

This places MK-PD2 in the High-Potency Therapeutic Candidate Tier.

Target Indications

Our therapeutic platform focuses on diseases driven by inflammatory and immune signaling dysregulation.

Primary Indications

• Rheumatoid arthritis
• Inflammatory bowel disease
• Chronic systemic inflammation

Secondary Indications

• Solid tumors with protease-rich microenvironments
• Fibrotic diseases
• Autoimmune disorders

Development Progress

SCF BIOTECH Therapeutics is currently advancing the Maytenus krukovii platform through IND-enabling development.

Preclinical Program

• Molecular target validation
• Pharmacokinetic optimization
• Toxicology studies
• Efficacy testing in disease models

Clinical Pathway

Discovery
↓
Preclinical Development
↓
IND Submission
↓
Phase I Clinical Trials

Our goal is to initiate first-in-human clinical studies following regulatory approval.

Why SCF BIOTECH?

Synergistic Drug Discovery

Our Synergistic Compatibility Framework (SCF) allows us to design therapeutics that work with biological systems rather than against them.

Key advantages:

• multi-target therapeutic design
• improved safety profiles
• enhanced pharmacokinetic performance
• faster translational development

Strategic Vision

SCF BIOTECH Therapeutics is building a new generation of synergistic medicines that combine:

• traditional botanical knowledge
• advanced molecular engineering
• precision therapeutic design

The Maytenus krukovii platform represents the first of many SCF-engineered therapeutic systems currently under development.

Partner With Us

We are actively seeking partnerships with:

• pharmaceutical companies
• research institutions
• strategic investors

to accelerate development of our therapeutic pipeline.

SCF BIOTECH Therapeutics

Engineering the next generation of synergistic medicines.